BIODYNE CO., LTD.

314930KOSDAQMedical, precision and optical instruments

BIODYNE CO., LTD. (314930, KOSDAQ) reported KRW 7bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
20234-2-14443Separate
20245-204443Separate
20257114544Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023-50.2%-24.3%98.6%-2.3%
2024-32.8%0.2%97.4%0%
20259.3%12.1%98.1%1.9%

Revenue moved 71.9% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 213bn
Close priceKRW 7,140
Listed shares29,764,103
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)23
Women9 (39.1%)
Average tenure3.5 years
Annual pay, menKRW 33,724,286
Annual pay, womenKRW 47,467,667
Pay ratio, women to men140.8%

Other companies in Medical, precision and optical instruments

102 listed companies file under this classification. Showing 12.

See the whole Medical, precision and optical instruments list →